Search

everythinglearnresearchcommunity

for

Search:↓

The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.

A user's progress with hair loss treatments, including Dutasteride, Minoxidil (oral and topical), Microneedling, and RU58841, which resulted in positive results after 5 months. Another user commented on the faster growth at the front compared to the crown.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

Botox may help with hair regrowth, but the effectiveness of scalp massaging is uncertain. DHT is a factor in hair loss, but not the only cause.

The user has been using finasteride and minoxidil for hair loss since 2021, with some initial regrowth but now considering switching to dutasteride due to concerns about further hair loss. They also use microneedling and are exploring tretinoin, while others suggest adding oral minoxidil or a hair transplant for better results.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Micronutrient testing and deficiencies related to hair loss, particularly androgenetic alopecia (AGA). Discussion includes the impact of iron, selenium, zinc, copper, folate, B12, vitamin E, vitamin D, amino acids, and fatty acids, alongside treatments like dutasteride or finasteride.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Hair loss treatments, specifically finasteride and minoxidil, being used by wealthy individuals to combat their genetic predisposition to baldness. It also discussed other potential treatments such as RU58841 and dutasteride.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.

Melatonin is being considered as a potential treatment for androgenic alopecia, with some users discussing its effects and combining it with other treatments like minoxidil and finasteride. Concerns about melatonin's impact on hormones and side effects from other treatments like ketoconazole were also discussed.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

The conversation is about a hair loss treatment regimen that includes finasteride, dutasteride, oral minoxidil, Dermapen, quercetin, N-acetyl L-cysteine, biotin, millet seed extract, MSM, OPC, green tea extract, high-dose vitamins B1-B12, boron, and silica. The user is seeking advice on additional treatments.

Minoxidil and caffeine are discussed for hair loss treatment. The user questions the logic of combining them due to their opposing effects on adenosine receptors.

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

A user successfully regrew hair using 1mg finasteride, switching to 0.5mg dutasteride, and maintaining 5mg oral minoxidil, with significant improvements noted after switching to dutasteride. The user experienced shedding phases but ultimately achieved regrowth and is now comfortable without wearing a hat.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.

A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.

Topical dutasteride may have limited absorption due to its higher molecular mass compared to finasteride, potentially affecting its efficacy in suppressing DHT locally. Microneedling might enhance dutasteride absorption, possibly offering stronger local DHT suppression with fewer systemic effects.

Finasteride may affect blood sugar and metabolism, with some users reporting increased blood sugar and changes in body composition. To manage potential side effects, users suggest exercise, intermittent fasting, and dietary adjustments.

The conversation discusses using minoxidil and microneedling to potentially thicken small hairs on the forehead after a hair transplant. It also mentions the importance of using an oral DHT blocker for hair growth.